cloudhosting14 wrote: As you would already know that managed hosting itself is another form of Cloud hosting in which the system administrations of servers is looked upon by the CPs. Similar is the case with managed multi Cloud hosting. You can very well understand how a big burden it would be to manage multi cloud servers for organization; this is why a service known as managed multi Cloud is provided to these users. This service ensures them the seam less running of their system administrative operations while organizations focus more on t...
BEIJING, Nov. 15, 2012 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today its unaudited financial results for the third quarter ended September 30, 2012.
Third Quarter 2012Financial Highlights (year-over-year comparisons to third quarter 2011)
Hepatitis vaccines sales in private pay market rose 31.2%; total sales decreased 7.0% to $14.3 million.
Gross margin was 52.6%, compared to 56.8%.
Net loss attributable to common stockholders was $3.0 million, or $0.06 per basic and diluted share.
Cash and cash equivalents totaled $82.0 million as of September 30, 2012, compared to $104.3 million as of December 31, 2011.
Recent Business Highlights
-- Sales and Marketing
Both Bilive sales and Healive sales in the private pay market continued to exhibit solid year-over-year growth in the third quarter compared to the same period of 2011. In addition to the private pay market sales growth, Sinovac continues to execute its sales plan in the public market. In the past few months, the Company was awarded multiple provincial tender awards for both Healive and Anflu. Besides the tender awards in Gansu Province, Beijing, and Shanghai previously announced, in October, Sinovac was selected by Jiangsu Centers for Disease Control and Prevention (Jiangsu CDC) as one of the two vaccine manufacturers to supply inactivated hepatitis A vaccine for the EPI in Jiangsu province in 2013. In the third quarter, total sales were mainly impacted by the decrease of Healive revenue in the public market, and sales are expected to increase in the coming quarters after vaccine delivery.
-- Phase III Clinical Trial for EV71 Vaccine Candidate
The EV71 vaccine Phase III clinical trial is progressing on schedule. The hand, foot and mouth disease (HFMD) case surveillance is ongoing, and documentation collection, data input, data review, and quality control on the database are well underway and progressing on schedule.
-- Mumps Vaccine Progress
In the third quarter, Sinovac Biotech received Good Manufacturing Practices (GMP) certification from the China SFDA for the Company's dedicated mumps vaccine production plant at its Sinovac Dalian facility.
-- 2012 Annual General Meeting
On August 22, 2012, Sinovac held its 2012 Annual General Meeting of shareholders. During the meeting, four proposals, including the 2012 Share Incentive Plan were approved, while a fifth, a proposal to amend the Company's by-laws, was not approved.
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "During the third quarter 2012, our hepatitis vaccine business grew in the private pay market, while the Healive sales in the public market decreased compared to the same period of last year, impacting our total sales. In the coming quarters we expect sales of Healive in the public market will pick up, as we continue to improve our capabilities and expand our presence in that market."
Dr. Yin continued, "We expect the commercialization of our EV71 vaccine to become our key future growth catalyst. Currently, the Phase III clinical trial of our EV71 vaccine is being executed smoothly and moving forward well on schedule. We remain in close communication with the relevant authorities and experts on the expected schedule for trial conclusion and data unblinding, and we will share that information when appropriate."
Dr. Yin concluded, "Our cash position and credit line facilities with local commercial banks provide us with the resources to commercialize our EV71 vaccine being developed for HFMD. We are in the position to drive the future growth of our business with a combination of commercialized vaccines and vaccine candidates."
Financial Review for Third Quarter Ended September 30, 2012
An analysis of sales and gross profit is as follows:
In USD
2012Q3
% of Sales
2011Q3
%of Sales
Increase / - Decrease %
Hepatitis A – Healive
4,931,790
34.5%
5,595,358
36.4%
-11.9%
Hepatitis A&B – Bilive
5,548,237
38.9%
5,205,478
33.9%
6.6%
Hepatitis vaccines
10,480,027
73.4%
10,800,836
70.3%
-3.0%
Influenza vaccines
3,806,454
26.6%
4,560,961
29.7%
-16.5%
Animal vaccine
619
0.0%
Total sales
14,287,100
100%
15,361,797
100%
-7.0%
Cost of goods sold
6,770,712
47.4%
6,631,672
43.2%
2.1%
Gross profit
7,516,388
52.6%
8,730,125
56.8%
-13.9%
Total sales in the third quarter of 2012 decreased 7.0%, compared to $15.4 million in the same period of 2011.
The decrease in total third quarter 2012 sales were primarily due to decreased Healive sales to the public market and reduced Anflu sales that started later this year. This was partially offset by the increase of both Healive and Bilive sales in the private pay market. The Company ended the quarter with a net total sales decrease of $1.1 million, or 7.0%, compared to the same quarter of last year.
Core vaccines sales for the nine months period ended September 30, 2012, increased 6.0% to $29.6 million, compared to $28.0 million in the same period of 2011. Despite a 29.0% increase in Bilive sales, total sales decreased 17.0% to $29.6 million, compared to $35.7 million in the same period of last year. The decrease was mainly affected by non-core government stockpiling of the pandemic flu H5N1 vaccine sales of $7.7 million in the 2011 period, as there were no government stockpiling sales in the current fiscal year to date. Please refer to note 1 below for the sales analysis for the nine months period ended September 30, 2012.
Gross margin in third quarter of 2012 was 52.6%, compared to 56.8% in the same period of last year. The lower quarterly gross margin was mainly due to the increased provision for expired H1N1 inventory costs and overhead allocated to cost of goods sold arising from seasonal excess capacity. After deducting depreciation of land use rights, amortization of licenses and permits, the gross margin was 52.4% and 56.5% for the third quarter of 2012 and 2011, respectively.
Selling, general and administrative expenses as a percentage of third quarter 2012 sales were 54.9%, compared to 49.8% for the same quarter of the prior year. The increase in the year-over-year quarterly SG&A expenses was mainly due to the ongoing preparation costs for the GMP upgrade and the Changping site validation.
Research and development expenses for the third quarter were $3.8 million, a $1.4 million increase over the same period in 2011, mainly due to the ongoing EV71 clinical trial development.
The increase in depreciation of property, plant and equipment and amortization of licenses and permits for the third quarter of 2012 was mainly due to the assets at Changping site that were in use in the quarter.
As of September 30, 2012, cash and cash equivalents totaled $82.0 million, compared to $104.3 million as of December 31, 2012. The Company utilized $1.1 million and $6.5 million of its cash resources in the third quarter and nine months period, respectively, to contribute to its ongoing clinical trial for its proprietary EV71 vaccine. The Company intends to provide the trial with approximately an additional $3.4 million during the remaining quarter of the year and $1.5 million in 2013. During the quarter and the first nine months period, $3.7 million and $8.7 million, respectively, were spent for the ongoing capital needs of the Changping site development, which were in part covered by the credit line arrangements already in place. Capital expenditure payments to complete the Changping site, which are in part covered by the credit line arrangements, are estimated up to $7.0 million in the remaining quarter of 2012 and $8.7 million in 2013. The cash position and credit line facilities with local commercial banks provide the Company with the resources to commercialize the EV71 vaccine being developed for HFMD. The Company is in the position to drive the future growth of the business with a combination of commercialized vaccines and vaccine candidates.
Note 1
Sales Analysis for the Nine-month Period ended September 30, 2012
In USD
2012 1-9
% of sales
2011 1-9
%of sales
Increase / - Decrease %
Hepatitis A – Healive
10,104,218
34.1%
11,246,591
31.5%
-10.2%
Hepatitis A&B – Bilive
15,633,272
52.8%
12,116,369
33.9%
29.0%
Hepatitis vaccines
25,737,490
86.9%
23,362,960
65.4%
10.2%
Influenza vaccines
3,852,860
13.0%
4,588,828
12.9%
-16.0%
Animal vaccine
Core vaccines
34,849
29,625,199
0.1%
100%
-
27,951,788
-
78.3%
6.0%
H5N1
-
-
7,746,700
21.7%
Total sales
29,625,199
100%
35,698,488
100%
-17.0%
Cost of goods sold
10,401,918
35.1%
13,095,652
36.7%
-20.6%
Gross profit
19,223,281
64.9%
22,602,836
63.3%
-15.0%
Conference Call Details
The Company will host a conference call on Thursday, November 15, 2012 at 8:00 a.m. EST (November 15, 2012 at 9:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (International). A replay of the call will be available from 11 a.m. EST on November 15, 2012 to November 29, 2012 at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 403079.
A live audio webcast of the call will also be available from the investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning November 15, 2012, and the replay will remain available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza and mumps, as well as animal rabies vaccine. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the EV71 vaccine is currently in Phase III clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Helen Yang/Chris Lee Sinovac Biotech Ltd. Tel: +86-10-8279-9871/9659 Fax: +86-10-6296-6910 Email: ir@sinovac.com
Authorized 50,000,000 shares at par value of $0.001 each
Issued and outstanding: nil
Common stock
55,024
54,774
Authorized: 100,000,000 shares at par value of $0.001 each
Issued and outstanding: 55,023,461 (2011 –54,773,961)
Additional paid-in capital
106,204,800
105,383,346
Accumulated other comprehensive income
10,899,102
9,978,325
Statutory surplus reserves
11,808,271
11,808,271
Retained earnings(accumulated deficit)
(6,867,075)
2,696,227
Total stockholders' equity
122,100,122
129,920,943
Non-controlling interests
12,278,212
15,376,528
Total equity
134,378,334
145,297,471
Total liabilities and equity
209,956,018
215,908,129
SINOVAC BIOTECH LTD.
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Three and Nine Months Ended September 30, 2012 and 2011
(Unaudited)
(Expressed in U.S. Dollars)
Three months ended
Nine months ended
September 30
September 30
2012
2011
2012
2011
Sales
$
14,287,100
$
15,361,797
$
29,625,199
$
35,698,488
Cost of sales-(exclusive of depreciation of land-use rights and amortization of licenses and permits of $35,800 (2011 - $47,394) for three months and $107,770 (2011 -$257,019) for nine months
6,770,712
6,631,672
10,401,918
13,095,652
Gross profit
7,516,388
8,730,125
19,223,281
22,602,836
Selling, general and administrative expenses
7,844,861
7,644,466
18,865,676
16,730,771
Research and development expenses - net of
3,773,625
2,366,842
15,792,500
6,744,862
$nil (2011- $nil) for three months and $78,980(2011- $(215,431)) for nine months in government research grants
Depreciation of property, plant and equipment and amortization of licenses and permits
471,242
225,398
1,103,629
1,071,553
Provision for doubtful debts
97,067
1,226,456
97,067
1,226,456
Government grants recognized in income
(78,053)
(70,061)
(1,535,383)
(207,508)
Total operating expenses
12,108,742
11,393,101
34,323,489
25,566,134
Operating income (loss)
(4,592,354)
(2,662,976)
(15,100,208)
(2,963,298)
Interest income
464,512
333,797
1,561,039
841,766
Interest and financing expenses
302,846
(181,298)
(143,552)
(446,316)
Loss on disposal of equipment
(24,574)
(229,015)
(23,712)
(195,509)
Other income (Expenses)
(22,709)
135,033
109,142
157,414
Income (loss) before income taxes and non-controlling interests
(3,872,279)
(2,604,459)
(13,597,291)
(2,605,943)
Income tax recovery (expenses)
(5,958)
(271,230)
794,406
(2,056,723)
Consolidated net income (loss)
(3,878,237)
(2,875,689)
(12,802,885)
(4,662,666)
Less: income (loss) attributable to non-controlling interests
(849,619)
(733,453)
(3,239,583)
(1,049,116)
Net income (loss) attributable to stockholders
(3,028,618)
(2,142,236)
(9,563,302)
(3,613,550)
Net income (loss)
(3,878,237)
(2,875,689)
(12,802,885)
(4,662,666)
Other comprehensive income (loss)
Foreign currency translation adjustment
890,063
838,029
1,062,045
2,850,339
Total comprehensive income (loss)
(2,988,174)
(2,037,660)
(11,740,840)
(1,812,327)
Less: comprehensive income (loss) attributable to non-controlling interests
(744,732)
(619,032)
(3,098,315)
(622,407)
Comprehensive income(loss) attributable to stockholders
(2,243,442)
(1,418,628)
(8,642,525)
(1,189,920)
Basic and diluted earnings (loss) per share
-0.06
-0.04
-0.17
-0.07
Weighted average number of shares
of common stock outstanding
- Basic
55,023,070
54,674,182
54,881,874
54,504,318
- Diluted
55,023,070
54,674,182
54,881,874
54,504,318
SINOVAC BIOTECH LTD.
Consolidated Statements of Cash Flows
Three and Nine Months Ended September 30, 2012 and 2011
(Unaudited)
(Expressed in U.S. Dollars)
Three Months ended September 30
Nine Months ended September 30
2012
2011
2012
2011
Cash flows from (used in) operating activities
Net income(loss) for period
$
(3,878,237)
$
(2,875,689)
$
(12,802,885)
$
(4,662,666)
Adjustments to reconcile net income (loss) to net cash from
-
-
-
-
(used by) operating activities:
-
-
-
-
- deferred income taxes
5,958
285,838
72,287
2,056,723
-write-off of equipment and loss (gain) on disposal
24,574
229,015
23,712
195,509
FA Impairment provision
(21,106)
(17,784)
- unrealized foreign exchange gain
-
-
(43,880)
-
- stock-based compensation
134,138
63,759
388,104
164,392
- inventory provision
776,838
1,298,347
1,365,628
1,298,347
-provision for doubtful debt
97,067
1,226,456
97,067
1,226,456
- depreciation of property, plant and equipment, and amortization of licenses and permits
1,161,592
1,020,131
3,719,795
3,612,185
- research and development expenditures qualifying for government grant
(78,980)
(215,431)
- deferred government grant recognized in income
(68,712)
(70,061)
(1,446,925)
(207,508)
- accretion expenses
48,560
86,221
185,349
290,630
- accounts receivable
(6,631,251)
(4,648,768)
(7,302,483)
(271,247)
- inventories
1,287,997
820,897
(4,140,923)
(1,806,090)
- income tax payable
(375)
(17,984)
(3,124,852)
(523,917)
- prepaid expenses and deposits
560,264
88,351
1,048,642
(423,439)
- deferred revenue and advances from customers
1,456,127
1,812,241
1,356,605
(1,505,409)
- accounts payable and accrued liabilities
(1,213,161)
2,315,631
(3,735,436)
(1,870,927)
Net cash provided by (used in) operating activities
(6,259,727)
1,634,385
(24,436,959)
(2,642,392)
Cash flows from (used in) financing activities
- Loan proceeds
1,288,549
2,111,150
7,298,056
3,992,522
- Loan repayment
-
-
-
(1,383,338)
- Proceeds from issuance of common stock
5,760
197,852
399,200
734,400
- Repayment from non-controlling shareholder of Sinovac Beijing
-
-
-
3,397,522
- Subscriptions received
32,000
2,880
34,400
11,360
- Dividends paid to non-controlling shareholder of Sinovac Beijing
-
-
(799,376)
(5,862,676)
- Loan from non-controlling shareholder of Sinovac Dalian
-
3,178,164
-
- Government grant received
-
-
240,580
7,636
Net cash provided by (used in) financing activities
1,326,309
2,311,882
10,351,024
897,426
Cash flows used in investing activities
- Proceeds from disposal of equipment
-
117,292
-
117,292
- Proceeds from redemption of short-term investments
-
-
-
1,547,030
- Purchase of short-term investments
-
(9,845,966)
-
(32,277,897)
- Acquisition of property, plant and equipment
(4,322,153)
(2,945,723)
(10,941,774)
(8,643,864)
Net cash used in investing activities
(4,322,153)
(12,674,397)
(10,941,774)
(39,257,439)
Exchange effect on cash and cash equivalents
1,777,618
(163,169)
2,703,434
812,896
Increase (decrease) in cash and cash equivalents
(7,477,953)
(8,891,299)
(22,324,275)
(40,189,509)
Cash and cash equivalents, beginning of period
89,440,373
70,287,280
104,286,695
101,585,490
Cash and cash equivalents, end of period
81,962,420
61,395,981
81,962,420
61,395,981
Cash paid for interest
493,244
167,883
1,375,203
809,303
Cash paid for income taxes
-
866,693
520,514
Supplemental schedule of non-cash activities:
Acquisition of property, plant and equipment included in
SYS-CON Events announced today that Wowrack will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York.
Wowrack’s core expertise lies in high-availability Private and Public Cloud IaaS Hosti...
Big Data and the cloud each contributed a start-up to the stock market last Friday.
Tableau Software, a profitable chart-making BI data visualization firm, IPO’d on the Big Board in New York sporting the highly desirable ticker symbol DATA and selling at the open for $31 a shar...
SYS-CON Events announced today that nfina Technologies, a provider of highly reliable cloud server products, will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York.
nfina Technologies de...
SYS-CON Events announced today that OpenStack will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York. OpenStack software controls large pools of compute, storage, and networking resource...
“Cloud has everything to do with what has happened with Big Data,” explained Jason Deck, Director of Strategic Alliances at Logicworks, in this exclusive Q&A with Cloud Expo Conference Chair Jeremy Geelan. “Big Data doesn’t exist in its easily accessible way without cloud. From r...
.gif)
SYS-CON Events announced today that Wowrack will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York.
Wowrack’s core expertise lies in high-availability Private and Public Cloud IaaS Hosti...
Big Data and the cloud each contributed a start-up to the stock market last Friday.
Tableau Software, a profitable chart-making BI data visualization firm, IPO’d on the Big Board in New York sporting the highly desirable ticker symbol DATA and selling at the open for $31 a shar...
SYS-CON Events announced today that nfina Technologies, a provider of highly reliable cloud server products, will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York.
nfina Technologies de...
SYS-CON Events announced today that OpenStack will exhibit at SYS-CON's 12th International Cloud Expo, which will take place on June 10–13, 2013, at the Javits Center in New York City, New York. OpenStack software controls large pools of compute, storage, and networking resource...
“Cloud has everything to do with what has happened with Big Data,” explained Jason Deck, Director of Strategic Alliances at Logicworks, in this exclusive Q&A with Cloud Expo Conference Chair Jeremy Geelan. “Big Data doesn’t exist in its easily accessible way without cloud. From r...
